Medivation Company Profile (NASDAQ:MDVN)

About Medivation (NASDAQ:MDVN)

Medivation logoMedivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MDVN
  • CUSIP: 58501N10
  • Web:
Average Prices:
  • 50 Day Moving Avg: $77.41
  • 200 Day Moving Avg: $61.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 36.36
  • P/E Growth: 0.00
  • Net Margins: -195.92%
  • Return on Equity: -225.98%
  • Return on Assets: -108.55%
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 4.32%
  • Quick Ratio: 4.32%
  • Beta: 0.6

Frequently Asked Questions for Medivation (NASDAQ:MDVN)

What is Medivation's stock symbol?

Medivation trades on the NASDAQ under the ticker symbol "MDVN."

How were Medivation's earnings last quarter?

Medivation Inc (NASDAQ:MDVN) posted its quarterly earnings results on Tuesday, August, 9th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The business earned $206 million during the quarter, compared to analysts' expectations of $214.52 million. Medivation had a negative net margin of 195.92% and a negative return on equity of 225.98%. The firm's quarterly revenue was up 17.4% compared to the same quarter last year. During the same period last year, the company posted $0.58 earnings per share. View Medivation's Earnings History.

Who are some of Medivation's key competitors?

How do I buy Medivation stock?

Shares of Medivation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medivation's stock price today?

One share of Medivation stock can currently be purchased for approximately $81.44.

MarketBeat Community Rating for Medivation (NASDAQ MDVN)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  581 (Vote Outperform)
Underperform Votes:  345 (Vote Underperform)
Total Votes:  926
MarketBeat's community ratings are surveys of what our community members think about Medivation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Medivation (NASDAQ:MDVN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Medivation (NASDAQ:MDVN)
Price Target History for Medivation (NASDAQ:MDVN)
Analysts' Ratings History for Medivation (NASDAQ:MDVN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2016BMO Capital MarketsReiterated RatingHoldN/AView Rating Details
9/28/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
9/28/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
9/14/2016SunTrust Banks, Inc.Reiterated RatingNeutralN/AView Rating Details
8/22/2016Maxim GroupSet Price TargetBuy$76.00N/AView Rating Details
8/23/2016Credit Suisse GroupDowngradeOutperform -> Neutral$81.50N/AView Rating Details
8/23/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
8/22/2016Citigroup Inc.DowngradeBuy -> Neutral$73.00 -> $81.50N/AView Rating Details
8/22/2016WedbushDowngradeOutperform -> Neutral$81.50N/AView Rating Details
8/22/2016Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
8/22/2016Barclays PLCDowngradeOverweight -> Equal Weight$70.00 -> $81.00N/AView Rating Details
8/10/2016Leerink SwannSet Price TargetHold$64.00N/AView Rating Details
8/10/2016Jefferies Group LLCReiterated RatingHold$56.00 -> $60.00N/AView Rating Details
8/10/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
5/7/2016Royal Bank Of CanadaReiterated RatingSector Perform$40.00 -> $70.00N/AView Rating Details
5/4/2016MizuhoDowngradeNeutral -> Underperform$150.00N/AView Rating Details
5/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$44.00N/AView Rating Details
4/4/2016BTIG ResearchReiterated RatingHoldN/AView Rating Details
2/19/2016Bank of America CorpInitiated CoverageBuy$45.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperform$83.00N/AView Rating Details
(Data available from 10/16/2015 forward)


Earnings History for Medivation (NASDAQ:MDVN)
Earnings by Quarter for Medivation (NASDAQ:MDVN)
Earnings History by Quarter for Medivation (NASDAQ MDVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.27$0.29$214.52 million$206.00 millionViewN/AView Earnings Details
5/5/2016Q116$0.23$0.11$197.01 million$182.50 millionViewListenView Earnings Details
2/25/2016Q415$0.28$0.29$373.85 million$377.74 millionViewListenView Earnings Details
11/5/2015Q315$0.33$0.35$236.70 million$260.70 millionViewN/AView Earnings Details
8/6/2015Q215$0.45$0.58$155.22 million$175.67 millionViewN/AView Earnings Details
5/7/2015Q115$0.27$0.17$149.00 million$129.20 millionViewN/AView Earnings Details
2/25/2015Q414$1.33$1.96$233.19 million$274.70 millionViewN/AView Earnings Details
11/6/2014Q314$0.84$0.96$182.00 million$200.48 millionViewN/AView Earnings Details
8/7/2014Q214$0.24$0.60$126.46 million$148.09 millionViewN/AView Earnings Details
5/8/2014Q114($0.09)($0.18)$94.64 million$87.19 millionViewN/AView Earnings Details
2/27/2014Q413($0.08)$0.03$72.68 million$96.61 millionViewN/AView Earnings Details
1/30/2014Q4($0.14)($0.43)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.21)($0.07)$59.35 million$70.15 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.45)($0.36)$38.54 million$46.15 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.52)($0.43)$34.36 million$37.16 millionViewN/AView Earnings Details
11/9/2012Q312($0.03)($0.06)$52.11 million$64.80 millionViewN/AView Earnings Details
8/9/2012$0.23($0.15)ViewN/AView Earnings Details
5/8/2012$1.19$0.01ViewN/AView Earnings Details
2/29/2012($0.25)($0.31)ViewN/AView Earnings Details
11/9/2011($0.31)($0.29)ViewN/AView Earnings Details
8/9/2011($0.25)($0.27)ViewN/AView Earnings Details
5/6/2011($0.24)($0.24)ViewN/AView Earnings Details
3/16/2011($0.17)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Medivation (NASDAQ:MDVN)
Current Year EPS Consensus Estimate: $1.27 EPS
Next Year EPS Consensus Estimate: $2.24 EPS


Dividend History for Medivation (NASDAQ:MDVN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Medivation (NASDAQ:MDVN)
Insider Ownership Percentage: 3.54%
Institutional Ownership Percentage: 87.55%
Insider Trades by Quarter for Medivation (NASDAQ:MDVN)
Institutional Ownership by Quarter for Medivation (NASDAQ:MDVN)
Insider Trades by Quarter for Medivation (NASDAQ:MDVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016Andrew Kenneth William PowellSVPSell2,578$60.42$155,762.76View SEC Filing  
5/6/2016Rick BierlyCFOSell10,340$59.76$617,918.40View SEC Filing  
3/14/2016Dawn SvoronosDirectorSell6,000$38.90$233,400.00View SEC Filing  
3/4/2016David HungCEOSell5,085$41.10$208,993.50View SEC Filing  
3/4/2016Mohammad HirmandInsiderSell1,525$41.10$62,677.50View SEC Filing  
3/4/2016Rick BierlyCFOSell2,998$40.00$119,920.00View SEC Filing  
2/4/2016David HungCEOSell6,350$31.18$197,993.00View SEC Filing  
1/19/2016Clarence Patrick MachadoDirectorSell75,000$37.34$2,800,500.00View SEC Filing  
1/4/2016Joseph M LobackiInsiderSell3,065$46.50$142,522.50View SEC Filing  
12/14/2015W Anthony VernonDirectorBuy15,000$40.69$610,350.00View SEC Filing  
12/3/2015David HungCEOSell10,950$43.10$471,945.00View SEC Filing  
12/3/2015Mohammad HirmandInsiderSell1,075$43.40$46,655.00View SEC Filing  
9/25/2015Clarence Patrick MachadoDirectorSell71,980$42.36$3,049,072.80View SEC Filing  
9/8/2015Dawn SvoronosDirectorSell3,100$89.15$276,365.00View SEC Filing  
6/4/2015Clarence Patrick MachadoDirectorSell36,000$117.43$4,227,480.00View SEC Filing  
5/20/2015Rick BierlyCFOSell1,000$130.00$130,000.00View SEC Filing  
5/5/2015Rick BierlyCFOSell1,615$125.00$201,875.00View SEC Filing  
5/4/2015Rick BierlyCFOSell2,170$124.70$270,599.00View SEC Filing  
4/15/2015Rick BierlyCFOSell3,000$132.20$396,600.00View SEC Filing  
3/16/2015Jennifer J RhodesInsiderSell1,390$130.92$181,978.80View SEC Filing  
3/2/2015David HungCEOSell100,891$120.83$12,190,659.53View SEC Filing  
3/2/2015Dawn SvoronosDirectorSell3,350$119.75$401,162.50View SEC Filing  
3/2/2015Jennifer J RhodesInsiderSell2,000$122.00$244,000.00View SEC Filing  
2/27/2015Kathryn E FalbergDirectorBuy25,000$117.67$2,941,750.00View SEC Filing  
2/26/2015David HungCEOSell19,109$120.12$2,295,373.08View SEC Filing  
2/26/2015Jennifer J RhodesInsiderSell3,089$119.29$368,486.81View SEC Filing  
2/4/2015David HungCEOSell3,190$100.48$320,531.20View SEC Filing  
1/27/2015Clarence Patrick MachadoDirectorSell36,000$105.32$3,791,520.00View SEC Filing  
1/20/2015David HungCEOSell100,000$108.14$10,814,000.00View SEC Filing  
12/3/2014Clarence Patrick MachadoDirectorSell1,580$113.00$178,540.00View SEC Filing  
12/3/2014David HungCEOSell5,420$113.00$612,460.00View SEC Filing  
9/18/2014Lynn SeelyInsiderSell55,000$98.47$5,415,850.00View SEC Filing  
9/9/2014Lynn SeelyInsiderSell20,000$94.60$1,892,000.00View SEC Filing  
8/27/2014Lynn SeelyInsiderSell20,000$89.42$1,788,400.00View SEC Filing  
8/13/2014Lynn SeelyInsiderSell20,000$83.62$1,672,400.00View SEC Filing  
8/12/2014Lynn SeelyInsiderSell25,500$83.02$2,117,010.00View SEC Filing  
7/22/2014Lynn SeelyInsiderSell7,500$73.96$554,700.00View SEC Filing  
7/2/2014Lynn SeelyInsiderSell12,000$79.02$948,240.00View SEC Filing  
6/18/2014Lynn SeelyInsiderSell15,000$74.75$1,121,250.00View SEC Filing  
2/18/2014Clarence Patrick MachadoCFOSell40,000$82.79$3,311,600.00View SEC Filing  
2/11/2014Clarence Patrick MachadoCFOSell40,000$80.83$3,233,200.00View SEC Filing  
2/5/2014Clarence Patrick MachadoCFOSell40,000$73.46$2,938,400.00View SEC Filing  
1/28/2014Clarence Patrick MachadoCFOSell40,000$75.43$3,017,200.00View SEC Filing  
1/27/2014David HungCEOSell150,000$73.50$11,025,000.00View SEC Filing  
1/21/2014Clarence Patrick MachadoCFOSell40,000$76.29$3,051,600.00View SEC Filing  
1/21/2014Jennifer RhodesInsiderSell14,000$76.28$1,067,920.00View SEC Filing  
12/3/2013Clarence Patrick MachadoCFOSell5,425$62.66$339,930.50View SEC Filing  
12/3/2013David HungCEOSell15,050$62.61$942,280.50View SEC Filing  
10/24/2013Cheryl CohenInsiderSell50,000$64.25$3,212,500.00View SEC Filing  
8/2/2013Cheryl CohenInsiderSell25,000$59.31$1,482,750.00View SEC Filing  
7/5/2013David HungCEOSell30,885$55.45$1,712,573.25View SEC Filing  
7/3/2013Cheryl CohenInsiderSell25,000$54.01$1,350,250.00View SEC Filing  
10/4/2012David HungCEOSell50,000$57.92$2,896,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Medivation (NASDAQ:MDVN)
Latest Headlines for Medivation (NASDAQ:MDVN)
DateHeadline logoMedivation Founder Takes Helm at Axovant, Shares Spike - October 6 at 10:22 AM logoContrasting Summit Therapeutics PLC (SMMT) and Medivation (MDVN) - August 17 at 4:50 AM logoEvercore: Underfollowed Firm Has Great Potential - Seeking Alpha - August 9 at 4:31 AM logoClovis Looks Vastly Overpriced - Seeking Alpha - March 28 at 10:29 AM logoClovis Looks Vastly Overpriced - March 27 at 6:01 PM logoClovis, Tesaro Soar on Astrazeneca Phase Three News - February 17 at 2:34 PM logoPfizer May Be Another IBM - February 3 at 7:12 PM logoRecent Pfizer Press Releases - January 31 at 7:22 PM logoPfizer quarterly revenue slips 3 percent - January 31 at 7:22 PM logoThe Best Biopharma CEOs of 2016 Are... - December 19 at 10:32 AM logoAfter FDA Approval, Merck Posts Better-Than-Expected Earnings - October 25 at 11:10 AM logoPfizer (PFE) Closes Medivation (MDVN) Acquisition - - September 28 at 11:02 AM logoMEDIVATION, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Dis - September 28 at 11:01 AM



Medivation (MDVN) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.